DocDollars

Gilead Sciences, Inc.

CA · United States · Reporting entity ID 100000000108

Total reported 2019–2025
$756.8M
#20 of 2,960 reporting companies — 0.9% of all reported industry payments
$230.8M in general payments across 674,560 records, plus $526.1M in research funding across 50,278 records.

How it breaks down

General payments $230,763,079
Research funding $526,053,438

Where this comes from

Figures are from the CMS Open Payments “payments grouped by reporting entity” dataset, queried live. Reporting entities are applicable manufacturers and group purchasing organisations required to report under the Sunshine Act.

Summary

Gilead Sciences, Inc. reported $756.8M to US doctors and teaching hospitals from 2019 to 2025, ranking #20 of 2,960 reporting companies. 70% of that was research funding and 30% general payments such as consulting, speaking, food and travel. 674,560 general payment records and 50,278 research records were filed.

Common questions about Gilead Sciences, Inc.

How much has Gilead Sciences, Inc. paid US doctors?

Gilead Sciences, Inc. reported $756,816,517 to US physicians and teaching hospitals across the 2019–2025 Open Payments program years: $230,763,079 in general payments, $526,053,438 in research funding.

How does Gilead Sciences, Inc. rank among drug and device companies?

It ranks #20 of 2,960 reporting entities by total reported value, about 0.9% of all industry payments in the dataset.

Does a payment from Gilead Sciences, Inc. mean a doctor did something wrong?

No. Open Payments records transfers of value such as speaking fees, consulting, meals, travel and research funding. The data shows the relationship, not its effect on prescribing or care.